Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 641

1.

An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.

Girard L, Rodriguez-Canales J, Behrens C, Thompson DM, Botros IW, Tang H, Xie Y, Rekhtman N, Travis WD, Wistuba II, Minna JD, Gazdar AF.

Clin Cancer Res. 2016 Jun 28. pii: clincanres.2900.2015. [Epub ahead of print]

PMID:
27354471
2.

Correction: "From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers".

Gazdar AF, Hirsch FR, Minna JD.

J Thorac Oncol. 2016 Jul;11(7):e88-9. doi: 10.1016/j.jtho.2016.04.003. No abstract available.

PMID:
27339412
3.

A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Thu KL, Papari-Zareei M, Stastny V, Song K, Peyton M, Martinez VD, Zhang YA, Castro IB, Varella-Garcia M, Liang H, Xing C, Kittler R, Milchgrub S, Castrillon DH, Davidson HL, Reynolds CP, Lam WL, Lea J, Gazdar AF.

Oncotarget. 2016 Jun 10. doi: 10.18632/oncotarget.9929. [Epub ahead of print]

4.

Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.

Kim DW, Wu N, Kim YC, Cheng PF, Basom R, Kim D, Dunn CT, Lee AY, Kim K, Lee CS, Singh A, Gazdar AF, Harris CR, Eisenman RN, Park KS, MacPherson D.

Genes Dev. 2016 Jun 1;30(11):1289-99. doi: 10.1101/gad.279307.116.

PMID:
27298335
5.

Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer.

Gazdar AF, Minna JD.

J Natl Cancer Inst. 2016 May 31;108(10). pii: djw119. doi: 10.1093/jnci/djw119. Print 2016 Oct. No abstract available.

PMID:
27247352
6.

ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers.

Wang YW, Ma X, Zhang YA, Wang MJ, Yatabe Y, Lam S, Girard L, Chen JY, Gazdar AF.

J Thorac Oncol. 2016 May 24. pii: S1556-0864(16)30460-9. doi: 10.1016/j.jtho.2016.05.010. [Epub ahead of print]

PMID:
27234602
7.

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.

Frink RE, Peyton M, Schiller JH, Gazdar AF, Shay JW, Minna JD.

Oncotarget. 2016 May 12. doi: 10.18632/oncotarget.9335. [Epub ahead of print]

8.

Inhibiting the Jumonji family: a potential new clinical approach to targeting aberrant epigenetic mechanisms.

Martinez ED, Gazdar AF.

Epigenomics. 2016 Mar;8(3):313-6. doi: 10.2217/epi.15.115. Epub 2016 Feb 26. No abstract available.

PMID:
26918824
9.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

PMID:
26829312
10.

Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.

Zhang YA, Ma X, Sathe A, Fujimoto J, Wistuba II, Lam S, Yatabe Y, Wang YW, Stastny V, Gao B, Larsen JE, Girard L, Liu X, Song K, Behrens C, Kalhor N, Xie Y, Zhang MQ, Minna JD, Gazdar AF.

J Thorac Oncol. 2016 Mar;11(3):346-60. doi: 10.1016/j.jtho.2015.11.004. Epub 2015 Dec 25.

PMID:
26725182
11.

From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.

Gazdar AF, Hirsch FR, Minna JD.

J Thorac Oncol. 2016 Mar;11(3):287-99. doi: 10.1016/j.jtho.2015.10.009. Epub 2015 Dec 24. Review.

12.

Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma.

Soh J, Toyooka S, Matsuo K, Yamamoto H, Wistuba II, Lam S, Fong KM, Gazdar AF, Miyoshi S.

Oncol Lett. 2015 Sep;10(3):1775-1782. Epub 2015 Jun 23.

13.

Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer.

Hubaux R, Thu KL, Vucic EA, Pikor LA, Kung SH, Martinez VD, Mosslemi M, Becker-Santos DD, Gazdar AF, Lam S, Lam WL.

Int J Cancer. 2015 Nov 1;137(9):2072-82. doi: 10.1002/ijc.29577. Epub 2015 May 6.

PMID:
25907283
14.

Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival.

Schliekelman MJ, Taguchi A, Zhu J, Dai X, Rodriguez J, Celiktas M, Zhang Q, Chin A, Wong CH, Wang H, McFerrin L, Selamat SA, Yang C, Kroh EM, Garg KS, Behrens C, Gazdar AF, Laird-Offringa IA, Tewari M, Wistuba II, Thiery JP, Hanash SM.

Cancer Res. 2015 May 1;75(9):1789-800. doi: 10.1158/0008-5472.CAN-14-2535. Epub 2015 Mar 5.

15.

The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.

Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linnoila RI, MacPherson D, McFadden DG, Farago A, Jacks T, Travis WD, Brambilla E.

J Thorac Oncol. 2015 Apr;10(4):553-64. doi: 10.1097/JTO.0000000000000459.

16.

Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling.

Borkowski R, Du L, Zhao Z, McMillan E, Kosti A, Yang CR, Suraokar M, Wistuba II, Gazdar AF, Minna JD, White MA, Pertsemlidis A.

Cancer Res. 2015 Feb 15;75(4):666-75. doi: 10.1158/0008-5472.CAN-14-1329. Epub 2014 Dec 17.

17.

Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.

Taguchi A, Delgado O, Celiktaş M, Katayama H, Wang H, Gazdar AF, Hanash SM.

Proteomics. 2014 Dec;14(23-24):2750-9. doi: 10.1002/pmic.201400378. Epub 2014 Nov 20.

18.

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.

Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14788-93. doi: 10.1073/pnas.1410419111. Epub 2014 Sep 29.

19.

A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets.

Taguchi A, Taylor AD, Rodriguez J, Celiktaş M, Liu H, Ma X, Zhang Q, Wong CH, Chin A, Girard L, Behrens C, Lam WL, Lam S, Minna JD, Wistuba II, Gazdar AF, Hanash SM.

Cancer Res. 2014 Sep 1;74(17):4694-705. doi: 10.1158/0008-5472.CAN-13-3725. Epub 2014 Jun 26.

20.

Analysis of TP53 mutation status in human cancer cell lines: a reassessment.

Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF, Soussi T.

Hum Mutat. 2014 Jun;35(6):756-65. doi: 10.1002/humu.22556. Epub 2014 May 6. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk